VRTX Q3 2021 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$125B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.0B+29.0% YoY

Gross Profit

$1.7B88.1% margin

Operating Income

$1.1B53.1% margin

Net Income

$852M42.9% margin

EPS (Diluted)

$3.28

QoQ Revenue Growth

+10.6%

Cash Flow

Operating Cash Flow

$927M

Free Cash Flow

$875M

Stock-Based Comp.

$103M

Balance Sheet

Total Assets

$12.6B

Total Liabilities

$3.1B

Stockholders' Equity

$9.5B

Cash & Equivalents

$6.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.0B	$1.5B	+29.0%
Gross Profit	$1.7B	$1.4B	+29.3%
Operating Income	$1.1B	$672M	+56.9%
Net Income	$852M	$667M	+27.6%

Revenue Segments

TRIKAFTA/KAFTRIO

$1.6B78%

ORKAMBI

$185M9%

KALYDECO

$162M8%

SYMDEKO/SYMKEVI

$81M4%

Geographic Segments

UNITED STATES

$1.4B70%

Europe

$519M26%

Other, Non U.S.

$82M4%